 | |
| Clinical data | |
|---|---|
| Trade names | Vyndaqel, Vyndamax, others |
| Other names | Tafamidis meglumine |
| AHFS/ Drugs.com | Monograph |
| License data | |
|
Pregnancy category |
|
|
Routes of administration | By mouth |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C14H7Cl2NO3 |
| Molar mass | 308.11 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
 
(what is this?)
(verify) | |
Tafamidis, sold under the brand names Vyndaqel among others, is a medication used to treat transthyretin-mediated amyloidosis. [5] It is taken by mouth. [6] It can be stopped after liver transplantation. [6]
Common side effects include abdominal pain, diarrhea, and infection. [6] Use during pregnancy is believed to harm the baby. [8] It works by stabilizing the protein transthyretin, thus decreasing the formulation amyloids. [4]
Tafamidis was approved for medical use in Europe in 2011 and the United States in 2019. [4] [5] In the United Kingdom a month of 20 mg per day costs the NHS about £10,700 as of 2021. [6] This amount in the United States costs about 4,900 USD. [9]
References
- ^ a b "Vyndamax and Vyndaqel Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 17 July 2020. Archived from the original on 29 August 2021. Retrieved 16 August 2020.
- ^ "Vyndaqel 20 mg soft capsules - Summary of Product Characteristics". Electronic Medicines Compendium. Archived from the original on 2 April 2018. Retrieved 2 April 2018.
- ^ "Vyndaqel- tafamidis meglumine capsule, liquid filled Vyndamax- tafamidis capsule, liquid filled". DailyMed. 30 August 2019. Archived from the original on 1 April 2020. Retrieved 24 November 2019.
- ^ a b c "Vyndaqel EPAR". European Medicines Agency (EMA). 16 October 2019. Archived from the original on 25 November 2019. Retrieved 24 November 2019.
- ^ a b c d "Tafamidis Monograph for Professionals". Drugs.com. Archived from the original on 9 July 2021. Retrieved 7 August 2021.
- ^
a
b
c
d
e
f BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 428.
ISBN
978-0-85711-369-6.
{{ cite book}}: CS1 maint: date format ( link) - ^ "Tafamidis Use During Pregnancy". Drugs.com. 6 September 2019. Archived from the original on 11 July 2021. Retrieved 16 August 2020.
- ^ "Tafamidis Use During Pregnancy". Drugs.com. Archived from the original on 11 July 2021. Retrieved 16 September 2021.
- ^ "Vyndaqel Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 16 September 2021.
|
| |
| Clinical data | |
|---|---|
| Trade names | Vyndaqel, Vyndamax, others |
| Other names | Tafamidis meglumine |
| AHFS/ Drugs.com | Monograph |
| License data | |
|
Pregnancy category |
|
|
Routes of administration | By mouth |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C14H7Cl2NO3 |
| Molar mass | 308.11 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
|
(what is this?)
(verify) | |
Tafamidis, sold under the brand names Vyndaqel among others, is a medication used to treat transthyretin-mediated amyloidosis. [5] It is taken by mouth. [6] It can be stopped after liver transplantation. [6]
Common side effects include abdominal pain, diarrhea, and infection. [6] Use during pregnancy is believed to harm the baby. [8] It works by stabilizing the protein transthyretin, thus decreasing the formulation amyloids. [4]
Tafamidis was approved for medical use in Europe in 2011 and the United States in 2019. [4] [5] In the United Kingdom a month of 20 mg per day costs the NHS about £10,700 as of 2021. [6] This amount in the United States costs about 4,900 USD. [9]
References
- ^ a b "Vyndamax and Vyndaqel Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 17 July 2020. Archived from the original on 29 August 2021. Retrieved 16 August 2020.
- ^ "Vyndaqel 20 mg soft capsules - Summary of Product Characteristics". Electronic Medicines Compendium. Archived from the original on 2 April 2018. Retrieved 2 April 2018.
- ^ "Vyndaqel- tafamidis meglumine capsule, liquid filled Vyndamax- tafamidis capsule, liquid filled". DailyMed. 30 August 2019. Archived from the original on 1 April 2020. Retrieved 24 November 2019.
- ^ a b c "Vyndaqel EPAR". European Medicines Agency (EMA). 16 October 2019. Archived from the original on 25 November 2019. Retrieved 24 November 2019.
- ^ a b c d "Tafamidis Monograph for Professionals". Drugs.com. Archived from the original on 9 July 2021. Retrieved 7 August 2021.
- ^
a
b
c
d
e
f BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 428.
ISBN
978-0-85711-369-6.
{{ cite book}}: CS1 maint: date format ( link) - ^ "Tafamidis Use During Pregnancy". Drugs.com. 6 September 2019. Archived from the original on 11 July 2021. Retrieved 16 August 2020.
- ^ "Tafamidis Use During Pregnancy". Drugs.com. Archived from the original on 11 July 2021. Retrieved 16 September 2021.
- ^ "Vyndaqel Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 16 September 2021.